{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:19:59Z","timestamp":1789438799818,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EU4Health Program, European Union","award":["101102733"],"award-info":[{"award-number":["101102733"]}]},{"name":"EU4Health Program, European Union","award":["101102733"],"award-info":[{"award-number":["101102733"]}]},{"name":"Coronavirus Network (CoViNet), World Health Organization"},{"DOI":"10.13039\/501100002999","name":"Ministerie van Volksgezondheid, Welzijn en Sport","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The disease burden of COVID-19 significantly decreased with the implementation of vaccines. However, SARS-CoV-2 variants that escape vaccine induced immunity continue to emerge and may pose a risk to public health. While vaccine updates are available, it remains uncertain whether they are required for full protection. Here, we antigenically characterized SARS-CoV-2 variants JN.1, KP.2, KP.3.1.1, XEC and LP.8.1 by antigenic cartography and evaluated in vivo protection of JN.1 vaccination in hamsters. Antigenic cartography revealed that these variants are antigenically closely related. In vivo experiments showed that JN.1 vaccination blocked viral replication and inflammation in the lower respiratory tract of JN.1, KP.2 and KP.3.1.1 infected animals. However, despite close antigenic proximity, KP.3.1.1 infected JN.1 vaccinated animals showed evidence of viral replication in the upper respiratory tract, indicative for immune escape. These data demonstrate the strength of combining antigenic cartography with experimental challenge studies to study SARS-CoV-2 immune escape for vaccine updates.<\/jats:p>","DOI":"10.1038\/s41541-025-01348-x","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:37:28Z","timestamp":1767418648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Assessment of SARS-CoV-2 immune escape using antigenic cartography combined with experimental challenge studies"],"prefix":"10.1038","volume":"11","author":[{"given":"Merel R.","family":"te Marvelde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Z.","family":"Mykytyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin J. B.","family":"Veldhuis Kroeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre H. J.","family":"Bouffier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debby","family":"van Eck\u2014Schipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"van den Doel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Handrejk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Koel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Rissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Haagmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"1348_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","volume":"21","author":"PV Markov","year":"2023","unstructured":"Markov, P. V. et al. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 21, 361\u2013379 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"1348_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.3390\/vaccines12111236","volume":"12","author":"N Chen","year":"2024","unstructured":"Chen, N. et al. Comparative analysis of host cell entry efficiency and neutralization sensitivity of emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1. Vaccines 12, 1236 (2024).","journal-title":"Vaccines"},{"key":"1348_CR3","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1016\/S1473-3099(23)00744-2","volume":"24","author":"S Yang","year":"2024","unstructured":"Yang, S. et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 24, e70\u2013e72 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-01016-6","volume":"9","author":"K Xu","year":"2024","unstructured":"Xu, K. et al. Neutralization of SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 by human and murine sera. npj Vaccines 9, 215 (2024).","journal-title":"npj Vaccines"},{"key":"1348_CR5","doi-asserted-by":"publisher","first-page":"101850","DOI":"10.1016\/j.xcrm.2024.101850","volume":"5","author":"AL Roederer","year":"2024","unstructured":"Roederer, A. L. et al. Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity. Cell Rep. Med. 5, 101850 (2024).","journal-title":"Cell Rep. Med."},{"key":"1348_CR6","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1016\/S1473-3099(23)00813-7","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 24, e82 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"#cr-split#-1348_CR7.1","unstructured":"Organization, W. H. Statement on the antigen composition of COVID-19 vaccines. 14-05-2025 [cited 2025 03-04-2025]"},{"key":"#cr-split#-1348_CR7.2","unstructured":"Available from: https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines (2024)."},{"key":"1348_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1637\/8740-032509-ResNote.1","volume":"54","author":"RAM Fouchier","year":"2010","unstructured":"Fouchier, R. A. M. & Smith, D. J. Use of antigenic cartography in vaccine seed strain selection. Avian Dis. 54, 220\u2013223 (2010).","journal-title":"Avian Dis."},{"key":"1348_CR9","doi-asserted-by":"publisher","first-page":"eabq4450","DOI":"10.1126\/sciimmunol.abq4450","volume":"7","author":"AZ Mykytyn","year":"2022","unstructured":"Mykytyn, A. Z. et al. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. Sci. Immunol. 7, eabq4450 (2022).","journal-title":"Sci. Immunol."},{"key":"1348_CR10","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1016\/S2666-5247(22)00384-6","volume":"4","author":"AZ Mykytyn","year":"2023","unstructured":"Mykytyn, A. Z. et al. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1. Lancet Microbe 4, e294\u2013e295 (2023).","journal-title":"Lancet Microbe"},{"key":"1348_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41049-4","volume":"14","author":"A R\u00f6ssler","year":"2023","unstructured":"R\u00f6ssler, A. et al. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography. Nat. Commun. 14, 5224 (2023).","journal-title":"Nat. Commun."},{"key":"1348_CR12","doi-asserted-by":"publisher","first-page":"115140","DOI":"10.1016\/j.celrep.2024.115140","volume":"44","author":"A R\u00f6ssler","year":"2025","unstructured":"R\u00f6ssler, A. et al. Nonhuman primate antigenic cartography of SARS-CoV-2. Cell Rep. 44, 115140 (2025).","journal-title":"Cell Rep."},{"key":"1348_CR13","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-08315-x","volume":"637","author":"F Jian","year":"2025","unstructured":"Jian, F. et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature 637, 921\u2013929 (2025).","journal-title":"Nature"},{"key":"1348_CR14","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1016\/S1473-3099(24)00810-7","volume":"25","author":"K Uriu","year":"2025","unstructured":"Uriu, K. et al. Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC. Lancet Infect. Dis. 25, e61 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR15","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S1473-3099(24)00603-0","volume":"24","author":"C Happle","year":"2024","unstructured":"Happle, C. et al. Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination. Lancet Infect. Dis. 24, e674\u2013e676 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR16","doi-asserted-by":"publisher","first-page":"e732","DOI":"10.1016\/S1473-3099(24)00688-1","volume":"24","author":"P Arora","year":"2024","unstructured":"Arora, P. et al. Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC. Lancet Infect. Dis. 24, e732\u2013e733 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR17","doi-asserted-by":"publisher","first-page":"126869","DOI":"10.1016\/j.vaccine.2025.126869","volume":"52","author":"O Diya","year":"2025","unstructured":"Diya, O. et al. A phase 2\/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults \u226518 years old. Vaccine 52, 126869 (2025).","journal-title":"Vaccine"},{"key":"1348_CR18","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1016\/S1473-3099(25)00079-9","volume":"25","author":"L Chen","year":"2025","unstructured":"Chen, L. et al. Virological characteristics of the SARS-CoV-2 LP.8.1 variant. Lancet Infect. Dis. 25, e193 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR19","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S1473-3099(25)00113-6","volume":"25","author":"L Zhang","year":"2025","unstructured":"Zhang, L. et al. Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1. Lancet Infect. Dis. 25, e196\u2013e197 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR20","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S1473-3099(24)00731-X","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 XEC variant. Lancet Infect. Dis. 24, e736 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR21","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1016\/S1473-3099(25)00015-5","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1. Lancet Infect. Dis. 25, e128\u2013e130 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR22","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S1473-3099(25)00007-6","volume":"25","author":"MS Suthar","year":"2025","unstructured":"Suthar, M. S. et al. The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant. Lancet Infect. Dis. 25, e122\u2013e123 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D. et al. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326 (2022).","journal-title":"Immunol. Rev."},{"key":"1348_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","volume":"2025","author":"R Link-Gelles","year":"2025","unstructured":"Link-Gelles, R. et al. Interim estimates of 2024\u20132025 COVID-19 vaccine effectiveness among adults aged \u226518 years \u2014 visioN and IVY Networks September 2024\u2013January 2025. MMWR Morb. Mortal. Wkly Rep. 2025, 73\u201382 (2025).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1348_CR25","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1093\/cid\/ciaa325","volume":"71","author":"JF-W Chan","year":"2020","unstructured":"Chan, J. F.-W. et al. Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in a golden syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis. 71, 2428\u20132446 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"1348_CR26","doi-asserted-by":"publisher","first-page":"e00948-24","DOI":"10.1128\/jvi.00948-24","volume":"98","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1. J. Virol. 98, e00948-24 (2024).","journal-title":"J. Virol."},{"key":"1348_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00888-y","volume":"9","author":"A R\u00f6ssler","year":"2024","unstructured":"R\u00f6ssler, A. et al. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera. npj Vaccines 9, 85 (2024).","journal-title":"npj Vaccines"},{"key":"1348_CR28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/s41586-024-07539-1","volume":"630","author":"C-Y Liang","year":"2024","unstructured":"Liang, C.-Y. et al. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Nature 630, 950\u2013960 (2024).","journal-title":"Nature"},{"key":"1348_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-84138-0","volume":"15","author":"N Suntronwong","year":"2025","unstructured":"Suntronwong, N. et al. Neutralization of omicron subvariants and antigenic cartography following multiple COVID 19 vaccinations and repeated omicron non JN.1 or JN.1 infections. Sci. Rep. 15, 1454 (2025).","journal-title":"Sci. Rep."},{"key":"1348_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55938-3","volume":"16","author":"A Wickenhagen","year":"2025","unstructured":"Wickenhagen, A. et al. Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology. Nat. Commun. 16, 594 (2025).","journal-title":"Nat. Commun."},{"key":"1348_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00528-24","volume":"98","author":"N Soudani","year":"2024","unstructured":"Soudani, N. et al. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters. J. Virol. 98, e0052824 (2024).","journal-title":"J. Virol."},{"key":"1348_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41392-021-00809-8","volume":"6","author":"Y Gong","year":"2021","unstructured":"Gong, Y. et al. The glycosylation in SARS-CoV-2 and its receptor ACE2. Signal Transduct. Target. Ther. 6, 396 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1348_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00242-25","volume":"0","author":"P Li","year":"2025","unstructured":"Li, P. et al. Role of glycosylation mutations at the N-terminal domain of SARS-CoV-2 XEC variant in immune evasion, cell-cell fusion, and spike stability. J. Virol. 0, e00242-25 (2025).","journal-title":"J. Virol."},{"key":"1348_CR34","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S1473-3099(24)00738-2","volume":"25","author":"J Liu","year":"2025","unstructured":"Liu, J. et al. Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations. Lancet Infect. Dis. 25, e6\u2013e7 (2025).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR35","doi-asserted-by":"publisher","first-page":"e477","DOI":"10.1016\/S1473-3099(24)00377-3","volume":"24","author":"D Geers","year":"2024","unstructured":"Geers, D. et al. Profiling the SARS-CoV-2-specific T-cell response. Lancet Infect. Dis. 24, e477\u2013e478 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR36","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1016\/S1473-3099(24)00155-5","volume":"24","author":"DL Wannigama","year":"2024","unstructured":"Wannigama, D. L. et al. Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1. Lancet Infect. Dis. 24, e348\u2013e350 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1348_CR37","doi-asserted-by":"crossref","unstructured":"Degryse, J. et al., Antigenic imprinting dominates humoral responses to new variants of SARS-CoV-2 in a Hamster Model of COVID-19. Microorganisms, 12, (2024).","DOI":"10.1101\/2024.10.30.621174"},{"key":"1348_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.abf4896","volume":"371","author":"RD de Vries","year":"2021","unstructured":"de Vries, R. D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science 371, 1379\u20131382 (2021).","journal-title":"Science"},{"key":"1348_CR39","doi-asserted-by":"crossref","unstructured":"Corman, V. M. et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill, 25 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"},{"key":"1348_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jim.2011.02.004","volume":"368","author":"M Zivcec","year":"2011","unstructured":"Zivcec, M. et al. Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus). J. Immunol. Methods 368, 24\u201335 (2011).","journal-title":"J. Immunol. Methods"},{"key":"1348_CR41","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1126\/science.abb7314","volume":"368","author":"B Rockx","year":"2020","unstructured":"Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012\u20131015 (2020).","journal-title":"Science"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01348-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01348-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01348-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T08:48:07Z","timestamp":1769503687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01348-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1348"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01348-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7120432\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}